Jessica A. Atkinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessica A. Atkinson has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Anthea C. Lindquist
Affiliations Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia, Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Melbourne, Victoria, Australia
5 shared publications - Stephen Tong
Perinatal Epidemiology Group, Department of Obstetrics, Gynaecology, and Newborn Health The University of Melbourne Melbourne Victoria Australia
5 shared publications Susan P. Walker
Perinatal Epidemiology Group, Department of Obstetrics, Gynaecology, and Newborn Health The University of Melbourne Melbourne Victoria Australia
5 shared publications- Hannah Gordon
Perinatal Epidemiology Group, Department of Obstetrics, Gynaecology, and Newborn Health The University of Melbourne Melbourne Victoria Australia
4 shared publications - Roxanne Hastie
Perinatal Epidemiology Group, Department of Obstetrics, Gynaecology, and Newborn Health, University of Melbourne, Melbourne, Victoria, Australia
4 shared publications Richard J. Hiscock
Perinatal Epidemiology Group, Department of Obstetrics, Gynaecology, and Newborn Health The University of Melbourne Melbourne Victoria Australia
3 shared publications
Latest Publications
- Open Access
- 8 November 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Epidural in Labour and Obstetric Anal Sphincter Injury Risk: A Systematic Review and Meta‐Analysis
Background: Perineal injury during childbirth is common. The most severe injuries involve damage to the anal sphincter (obstetric anal sphincter injuries). Epidural analgesia provides effective labour pain relief but its impact on the risk of obstetric anal sphincter injury is unclear. Objective: To determine the association between epidural analgesia and the likelihood of obstetric anal sphincter injuries. Search Strategy: Ovid MEDLINE, Ovid EMBASE, PubMed, CINAHL and Web of Science were searched from database inception to October 18, 2025, using key words relating to epidural, perineal trauma and labour. Selection Criteria: Randomised trials and observational studies (cohort, case–control, and cross‐sectional studies) were included. Data Collection and Analysis: Studies reporting the same outcomes were pooled, and odds ratios with 95% confidence intervals were calculated using a random effects meta‐analysis. Main Results: From 24 977 identified studies, 86 were included ( N = 9 826 330 women). Pooled adjusted analyses showed epidural use in labour was associated with a 15% reduced likelihood of obstetric anal sphincter injury in the overall population ( n = 9 302 188; aOR 0.85 [95% CI 0.80–0.91]). Among nulliparous women, there was a 23% reduced likelihood of obstetric anal sphincter injury ( n = 1 083 923; aOR 0.77 [95% CI 0.71–0.83]). Conclusion: After pooling effect measures that corrected for important clinical confounders, our meta‐analysis suggests that epidural use in labour may reduce the likelihood of obstetric anal sphincter injuries among nulliparous women. While our findings must be interpreted within the limitations of observational data, they provide valuable evidence to guide clinical practice and highlight the need for more high‐quality studies to establish causality. Trial Registration: PROSPERO Registration CRD42023412771, 09 April 2023 https://www.crd.york.ac.uk/PROSPERO/view/CRD42023412771
- 8 November 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Open AccessEpidural in Labour and Obstetric Anal Sphincter Injury Risk: A Systematic Review and Meta‐Analysis
Background: Perineal injury during childbirth is common. The most severe injuries involve damage to the anal sphincter (obstetric anal sphincter injuries). Epidural analgesia provides effective labour pain relief but its impact on the risk of obstetric anal sphincter injury is unclear. Objective: To determine the association between epidural analgesia and the likelihood of obstetric anal sphincter injuries. Search Strategy: Ovid MEDLINE, Ovid EMBASE, PubMed, CINAHL and Web of Science were searched from database inception to October 18, 2025, using key words relating to epidural, perineal trauma and labour. Selection Criteria: Randomised trials and observational studies (cohort, case–control, and cross‐sectional studies) were included. Data Collection and Analysis: Studies reporting the same outcomes were pooled, and odds ratios with 95% confidence intervals were calculated using a random effects meta‐analysis. Main Results: From 24 977 identified studies, 86 were included ( N = 9 826 330 women). Pooled adjusted analyses showed epidural use in labour was associated with a 15% reduced likelihood of obstetric anal sphincter injury in the overall population ( n = 9 302 188; aOR 0.85 [95% CI 0.80–0.91]). Among nulliparous women, there was a 23% reduced likelihood of obstetric anal sphincter injury ( n = 1 083 923; aOR 0.77 [95% CI 0.71–0.83]). Conclusion: After pooling effect measures that corrected for important clinical confounders, our meta‐analysis suggests that epidural use in labour may reduce the likelihood of obstetric anal sphincter injuries among nulliparous women. While our findings must be interpreted within the limitations of observational data, they provide valuable evidence to guide clinical practice and highlight the need for more high‐quality studies to establish causality. Trial Registration: PROSPERO Registration CRD42023412771, 09 April 2023 https://www.crd.york.ac.uk/PROSPERO/view/CRD42023412771
- Open Access
- 5 November 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Periconceptual Progesterone Use and Hypertensive Disorders of Pregnancy: A Population‐Based Cohort Study
Objective: To investigate whether periconceptual use of progesterone is associated with an altered risk of new‐onset hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, or superimposed preeclampsia). Design: Population‐based cohort study using statewide pregnancy and birth data from Victoria, Australia, linked with hospital and medication prescribing data. Setting: Victoria, Australia (2009–2020). Population: Nulliparous women who gave birth between 2009 and 2020 in Victoria, Australia. Women with missing delivery dates, medicine dispensation dates, or who were exposed to progesterone in the second or third trimester were excluded. Methods: We compared nulliparous women exposed to progesterone in the periconceptual period (6 weeks preconception until the end of the first trimester) with those not exposed to progesterone. Inverse probability‐weighted regression adjustment was used to control for confounding factors and investigate the effect of progesterone on the risk of preeclampsia (including superimposed preeclampsia) and gestational hypertension. Main Outcome Measures: Development of preeclampsia or gestational hypertension. Results: Among 386 475 pregnancies, 5657 (1.5%) women used progesterone in the periconceptual period. Progesterone use was associated with a statistically significant reduction in the risk of any new onset hypertensive disorders of pregnancy (adjusted risk ratio [aRR] 0.81 [95% confidence interval [CI] 0.67, 0.98]; adjusted risk difference [aRD] −1.72% [95% CI −3.21%, −0.24%]). Investigating type of hypertension, we found progesterone use was associated with a 1.69% absolute reduced risk of gestational hypertension (aRR 0.60 [95% CI 0.43, 0.83]; aRD −1.69% [95% CI −2.52%, −0.86%]) but no significant change was observed for preeclampsia (aRR 0.97 [95% CI 0.75, 1.25]; aRD −0.13% [95% CI −1.49%, 1.23%]). Restricting our analyses to pregnancies conceived via assisted reproductive technology only, we found similar results, with a statistically significant reduction in the risk of gestational hypertension (aRR 0.80 [95% CI 0.67, 0.95]; aRD −1.02% [95% CI −1.73%, −0.30%]) but not preeclampsia (aRR 0.96 [95% CI 0.83, 1.11]; aRD −0.25% [95% CI −1.23%, 0.72%]). Conclusions: Among 386 475 nulliparous women, we found periconceptual progesterone use to be associated with a statistically significant reduction in the risk of gestational hypertension, but not preeclampsia. However, these findings are unlikely to be clinically meaningful.
- 5 November 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Open AccessPericonceptual Progesterone Use and Hypertensive Disorders of Pregnancy: A Population‐Based Cohort Study
Objective: To investigate whether periconceptual use of progesterone is associated with an altered risk of new‐onset hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, or superimposed preeclampsia). Design: Population‐based cohort study using statewide pregnancy and birth data from Victoria, Australia, linked with hospital and medication prescribing data. Setting: Victoria, Australia (2009–2020). Population: Nulliparous women who gave birth between 2009 and 2020 in Victoria, Australia. Women with missing delivery dates, medicine dispensation dates, or who were exposed to progesterone in the second or third trimester were excluded. Methods: We compared nulliparous women exposed to progesterone in the periconceptual period (6 weeks preconception until the end of the first trimester) with those not exposed to progesterone. Inverse probability‐weighted regression adjustment was used to control for confounding factors and investigate the effect of progesterone on the risk of preeclampsia (including superimposed preeclampsia) and gestational hypertension. Main Outcome Measures: Development of preeclampsia or gestational hypertension. Results: Among 386 475 pregnancies, 5657 (1.5%) women used progesterone in the periconceptual period. Progesterone use was associated with a statistically significant reduction in the risk of any new onset hypertensive disorders of pregnancy (adjusted risk ratio [aRR] 0.81 [95% confidence interval [CI] 0.67, 0.98]; adjusted risk difference [aRD] −1.72% [95% CI −3.21%, −0.24%]). Investigating type of hypertension, we found progesterone use was associated with a 1.69% absolute reduced risk of gestational hypertension (aRR 0.60 [95% CI 0.43, 0.83]; aRD −1.69% [95% CI −2.52%, −0.86%]) but no significant change was observed for preeclampsia (aRR 0.97 [95% CI 0.75, 1.25]; aRD −0.13% [95% CI −1.49%, 1.23%]). Restricting our analyses to pregnancies conceived via assisted reproductive technology only, we found similar results, with a statistically significant reduction in the risk of gestational hypertension (aRR 0.80 [95% CI 0.67, 0.95]; aRD −1.02% [95% CI −1.73%, −0.30%]) but not preeclampsia (aRR 0.96 [95% CI 0.83, 1.11]; aRD −0.25% [95% CI −1.23%, 0.72%]). Conclusions: Among 386 475 nulliparous women, we found periconceptual progesterone use to be associated with a statistically significant reduction in the risk of gestational hypertension, but not preeclampsia. However, these findings are unlikely to be clinically meaningful.
- Open Access
- 7 July 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Lithium Use in Pregnancy and the Risk of Spontaneous Preterm Birth: An Australian Statewide Retrospective Cohort Study
Objective: To investigate whether lithium exposure in pregnancy is associated with spontaneous preterm birth, congenital malformations and abnormal fetal growth. Design: Statewide retrospective cohort study. Setting: Victoria, Australia. Population: 867 454 births (2009–2020), including 234 (0.03%) exposed to lithium during pregnancy. Methods: Inverse probability weighted regression adjustment to investigate the association between maternal lithium use and perinatal outcomes. Main Outcome Measures: Spontaneous preterm birth (< 37 weeks' gestation), large for gestational age (LGA) (birthweight > 90th percentile), macrosomia (birthweight > 4000 g), major congenital malformations, congenital cardiac malformations. Results: Lithium use was associated a two‐fold increased risk of spontaneous preterm birth compared with unexposed pregnancies (8.1% vs. 2.4%; adjusted relative risk [aRR] 2.18, 95% CI 1.45–3.30). Lithium was associated with an increased risk of an LGA infant (13.7% vs. 6.4%; aRR 1.94, 95% CI 1.36–2.76), and congenital cardiac malformations (3.0% vs. 0.8%; aRR 2.64, 95% CI 1.26–5.53). Lithium was not associated with an altered risk of major congenital malformations overall (aRR 1.51, 95% CI 0.92–2.50). Restricting the cohort to women with bipolar disorder or schizophrenia diagnoses, associations remained between lithium exposure and spontaneous preterm birth (aRR 1.88, 95% CI 1.06–3.32) and birth of an LGA infant (aRR 1.68, 95% CI 1.07–2.65). Conclusions: In our study, lithium exposure during pregnancy was associated with a two‐fold increased risk of spontaneous preterm birth. Lithium use was also associated with an increased risk of cardiac malformations and having an LGA infant. These findings may be useful for shared decision‐making around lithium use during pregnancy.
- 7 July 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Open AccessLithium Use in Pregnancy and the Risk of Spontaneous Preterm Birth: An Australian Statewide Retrospective Cohort Study
Objective: To investigate whether lithium exposure in pregnancy is associated with spontaneous preterm birth, congenital malformations and abnormal fetal growth. Design: Statewide retrospective cohort study. Setting: Victoria, Australia. Population: 867 454 births (2009–2020), including 234 (0.03%) exposed to lithium during pregnancy. Methods: Inverse probability weighted regression adjustment to investigate the association between maternal lithium use and perinatal outcomes. Main Outcome Measures: Spontaneous preterm birth (< 37 weeks' gestation), large for gestational age (LGA) (birthweight > 90th percentile), macrosomia (birthweight > 4000 g), major congenital malformations, congenital cardiac malformations. Results: Lithium use was associated a two‐fold increased risk of spontaneous preterm birth compared with unexposed pregnancies (8.1% vs. 2.4%; adjusted relative risk [aRR] 2.18, 95% CI 1.45–3.30). Lithium was associated with an increased risk of an LGA infant (13.7% vs. 6.4%; aRR 1.94, 95% CI 1.36–2.76), and congenital cardiac malformations (3.0% vs. 0.8%; aRR 2.64, 95% CI 1.26–5.53). Lithium was not associated with an altered risk of major congenital malformations overall (aRR 1.51, 95% CI 0.92–2.50). Restricting the cohort to women with bipolar disorder or schizophrenia diagnoses, associations remained between lithium exposure and spontaneous preterm birth (aRR 1.88, 95% CI 1.06–3.32) and birth of an LGA infant (aRR 1.68, 95% CI 1.07–2.65). Conclusions: In our study, lithium exposure during pregnancy was associated with a two‐fold increased risk of spontaneous preterm birth. Lithium use was also associated with an increased risk of cardiac malformations and having an LGA infant. These findings may be useful for shared decision‐making around lithium use during pregnancy.
- Open Access
- 5 June 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 96, 104002
A comparison of the safety of oral labetalol versus nifedipine to manage hypertension in pregnancy in Australia: a target trial emulation
- 5 June 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 96, 104002
Open AccessA comparison of the safety of oral labetalol versus nifedipine to manage hypertension in pregnancy in Australia: a target trial emulation
- Open Access
- 28 April 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (4) , e1004994
Identifying novel prodromal symptoms of eclampsia: A two-country, case-control study
Background: Magnesium sulphate halves the risk of eclampsia. There is no consensus on who to give magnesium sulphate prophylaxis because clinical tools are poor at identifying those at risk. Known prodromal symptoms such as headache, visual disturbance, or epigastric pain have modest associations with eclampsia. We set out to identify new prodromal symptoms of eclampsia. Methods and findings: This case-control study prospectively recruited participants in South Africa and Pakistan who had eclampsia, preeclampsia, or normotensive pregnancies. We asked whether they experienced 20 neurological symptoms, within 7 days of the seizure for those who had eclampsia. The primary analysis was the likelihood of symptoms occurring before eclampsia, compared to being present with preeclampsia. 341 participants were recruited with eclampsia, 1,355 with preeclampsia and 389 with normotensive pregnancies. When comparing symptoms among those who had eclampsia versus preeclampsia, the odds ratios (OR) were 2.56 (95% confidence interval (CI) [1.81,3.62]; p < 0.001) for headache, 5.73 (95% CI [4.44,7.39]; p < 0.001) for visual disturbances and 2.25 (95% CI [1.76,2.89]; p < 0.001) for epigastric pain. We identified 10 symptoms with odds ratios over 10 for eclampsia. Odds ratios were 42.03 (95% CI [23.66,74.68]; p < 0.001) for twitching/jerking limbs (30.5% eclampsia versus 1% preeclampsia); 36.00 (95% CI [18.34,70.65]; p < 0.001) for affected hearing (21.1% versus 0.7%)’ 33.60 (95% CI [21.39,52.78]; p < 0.001) for affected mind state (38.7% versus 1.8%); 33.12 (95% CI [19.46, 54.37]; p < 0.001) for impaired speech; 23.71 (95% CI [16.49,34.10]; p < 0.001) for feelings of doom; 26.59 (95% CI [7.82,90.41]; p < 0.001) for severe vertigo; 20.52 (95% CI [14.22,29.63]; p < 0.001) for confusion; 18.16 (95% CI [10.76,30.66]; p < 0.001) for jitters; 15.18 (95% CI [11.34,20.33]; p < 0.001) for difficulty concentrating; and 10.49 (95% CI [6.76,16.27]; p < 0.001) for weakness/paralysis. These symptoms were rare among normotensive pregnancies. Only 2.4% of women with eclampsia did not experience any prodromal symptoms. This study is limited by the fact that we asked about prodromal symptoms after the seizure happened, and the potential for recall bias. Conclusions: Ten prodromal symptoms exhibit far stronger associations with eclampsia than headache, visual disturbances, or epigastric pain. Eclampsia is uncommon without any prodromal symptoms. It may be useful to screen these symptoms among women with preeclampsia as part of clinical history taking to guide management. They could help direct magnesium sulphate prophylaxis to those with a higher risk of eclampsia.
- 28 April 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (4) , e1004994
Open AccessIdentifying novel prodromal symptoms of eclampsia: A two-country, case-control study
Background: Magnesium sulphate halves the risk of eclampsia. There is no consensus on who to give magnesium sulphate prophylaxis because clinical tools are poor at identifying those at risk. Known prodromal symptoms such as headache, visual disturbance, or epigastric pain have modest associations with eclampsia. We set out to identify new prodromal symptoms of eclampsia. Methods and findings: This case-control study prospectively recruited participants in South Africa and Pakistan who had eclampsia, preeclampsia, or normotensive pregnancies. We asked whether they experienced 20 neurological symptoms, within 7 days of the seizure for those who had eclampsia. The primary analysis was the likelihood of symptoms occurring before eclampsia, compared to being present with preeclampsia. 341 participants were recruited with eclampsia, 1,355 with preeclampsia and 389 with normotensive pregnancies. When comparing symptoms among those who had eclampsia versus preeclampsia, the odds ratios (OR) were 2.56 (95% confidence interval (CI) [1.81,3.62]; p < 0.001) for headache, 5.73 (95% CI [4.44,7.39]; p < 0.001) for visual disturbances and 2.25 (95% CI [1.76,2.89]; p < 0.001) for epigastric pain. We identified 10 symptoms with odds ratios over 10 for eclampsia. Odds ratios were 42.03 (95% CI [23.66,74.68]; p < 0.001) for twitching/jerking limbs (30.5% eclampsia versus 1% preeclampsia); 36.00 (95% CI [18.34,70.65]; p < 0.001) for affected hearing (21.1% versus 0.7%)’ 33.60 (95% CI [21.39,52.78]; p < 0.001) for affected mind state (38.7% versus 1.8%); 33.12 (95% CI [19.46, 54.37]; p < 0.001) for impaired speech; 23.71 (95% CI [16.49,34.10]; p < 0.001) for feelings of doom; 26.59 (95% CI [7.82,90.41]; p < 0.001) for severe vertigo; 20.52 (95% CI [14.22,29.63]; p < 0.001) for confusion; 18.16 (95% CI [10.76,30.66]; p < 0.001) for jitters; 15.18 (95% CI [11.34,20.33]; p < 0.001) for difficulty concentrating; and 10.49 (95% CI [6.76,16.27]; p < 0.001) for weakness/paralysis. These symptoms were rare among normotensive pregnancies. Only 2.4% of women with eclampsia did not experience any prodromal symptoms. This study is limited by the fact that we asked about prodromal symptoms after the seizure happened, and the potential for recall bias. Conclusions: Ten prodromal symptoms exhibit far stronger associations with eclampsia than headache, visual disturbances, or epigastric pain. Eclampsia is uncommon without any prodromal symptoms. It may be useful to screen these symptoms among women with preeclampsia as part of clinical history taking to guide management. They could help direct magnesium sulphate prophylaxis to those with a higher risk of eclampsia.
- Open Access
- 10 September 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (9) , e1004558
Hypertensive disorders of pregnancy and childhood neurodevelopment: A systematic review and meta-analysis
Background: Hypertensive disorders of pregnancy may be associated with an increased risk of adverse neurodevelopmental outcomes for the child, though no recent comprehensive meta-analyses exist. The aim of this study was to conduct a systematic review and meta-analysis examining the association between hypertensive disorders of pregnancy and child neurodevelopmental disabilities, intelligence, and educational outcomes. Methods and findings: A search was conducted of MEDLINE, CINAHL, Web of Science, and PsycINFO databases from inception until 18 September 2024. Reference lists of included papers were also screened. Observational studies and secondary analyses of randomized trials reporting neurodevelopmental, cognitive, or educational outcomes for children born following hypertensive disorders of pregnancy against a reference population (unaffected pregnancies) were included. Two reviewers independently screened records, extracted data, and assessed quality of studies using Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Studies reporting similar outcomes were pooled using a random-effects meta-analysis model. Outcomes included autism, attention-deficit/hyperactivity disorder, cerebral palsy, global developmental delay, intellectual disability, intelligence quotient, and educational attainment. Results were reported as odds ratios (OR) or mean difference (MD) with corresponding 95% confidence intervals (CI). After screening 13,419 records, 121 studies reporting outcomes of 29,649,667 offspring were included. We included 85 cohort studies, 30 case-control studies, four cross-sectional studies, and two secondary analyses of randomized trials. Compared with unaffected pregnancies, hypertensive disorders of pregnancy were associated with an increased unadjusted likelihood of autism spectrum disorder (OR 1.65 (95% CI [1.49,1.83]); p < 0.001; n = 26,727,500), attention-deficit/hyperactivity disorder (OR 1.27 (95% CI [1.21,1.33]); p < 0.001; n = 12,987,737), intellectual disability (OR 1.77 (95% CI [1.31,2.38]); p < 0.001; n = 10,718,504), global developmental delay (OR 1.77 (95% CI [1.21,2.59]); p < 0.001; n = 2,961,195), and reduced mean intelligence (MD −2.20 95% CI [−3.35,-1.06]); p < 0.001; n = 1,150,664). Associations between hypertension and autism spectrum disorder and global developmental delay were no longer significant after adjusting for gestational age and birthweight. Results for intelligence quotient remained significant when adjusting for birthweight, but not gestational age. Adjusted analyses for attention-deficit/hyperactivity disorder and intellectual disability could not be performed due to a lack of suitable studies. In sensitivity analyses, results were unchanged after exclusion of papers at high risk of bias. This study is limited by a lack of constituent papers which adjusted for confounding and mediating factors, a high amount of heterogeneity among included studies, and possible publication bias for some outcomes. Conclusions: Hypertensive disorders of pregnancy are potentially associated with adverse neurodevelopmental and cognitive outcomes among affected offspring. While the mechanisms driving these associations are not clear, these results highlight a group of children that will benefit from early intervention and support to improve their neurodevelopmental outcomes.
- 10 September 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (9) , e1004558
Open AccessHypertensive disorders of pregnancy and childhood neurodevelopment: A systematic review and meta-analysis
Background: Hypertensive disorders of pregnancy may be associated with an increased risk of adverse neurodevelopmental outcomes for the child, though no recent comprehensive meta-analyses exist. The aim of this study was to conduct a systematic review and meta-analysis examining the association between hypertensive disorders of pregnancy and child neurodevelopmental disabilities, intelligence, and educational outcomes. Methods and findings: A search was conducted of MEDLINE, CINAHL, Web of Science, and PsycINFO databases from inception until 18 September 2024. Reference lists of included papers were also screened. Observational studies and secondary analyses of randomized trials reporting neurodevelopmental, cognitive, or educational outcomes for children born following hypertensive disorders of pregnancy against a reference population (unaffected pregnancies) were included. Two reviewers independently screened records, extracted data, and assessed quality of studies using Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Studies reporting similar outcomes were pooled using a random-effects meta-analysis model. Outcomes included autism, attention-deficit/hyperactivity disorder, cerebral palsy, global developmental delay, intellectual disability, intelligence quotient, and educational attainment. Results were reported as odds ratios (OR) or mean difference (MD) with corresponding 95% confidence intervals (CI). After screening 13,419 records, 121 studies reporting outcomes of 29,649,667 offspring were included. We included 85 cohort studies, 30 case-control studies, four cross-sectional studies, and two secondary analyses of randomized trials. Compared with unaffected pregnancies, hypertensive disorders of pregnancy were associated with an increased unadjusted likelihood of autism spectrum disorder (OR 1.65 (95% CI [1.49,1.83]); p < 0.001; n = 26,727,500), attention-deficit/hyperactivity disorder (OR 1.27 (95% CI [1.21,1.33]); p < 0.001; n = 12,987,737), intellectual disability (OR 1.77 (95% CI [1.31,2.38]); p < 0.001; n = 10,718,504), global developmental delay (OR 1.77 (95% CI [1.21,2.59]); p < 0.001; n = 2,961,195), and reduced mean intelligence (MD −2.20 95% CI [−3.35,-1.06]); p < 0.001; n = 1,150,664). Associations between hypertension and autism spectrum disorder and global developmental delay were no longer significant after adjusting for gestational age and birthweight. Results for intelligence quotient remained significant when adjusting for birthweight, but not gestational age. Adjusted analyses for attention-deficit/hyperactivity disorder and intellectual disability could not be performed due to a lack of suitable studies. In sensitivity analyses, results were unchanged after exclusion of papers at high risk of bias. This study is limited by a lack of constituent papers which adjusted for confounding and mediating factors, a high amount of heterogeneity among included studies, and possible publication bias for some outcomes. Conclusions: Hypertensive disorders of pregnancy are potentially associated with adverse neurodevelopmental and cognitive outcomes among affected offspring. While the mechanisms driving these associations are not clear, these results highlight a group of children that will benefit from early intervention and support to improve their neurodevelopmental outcomes.
- Top Cited PapersOpen Access
- 1 November 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (11) , e2343711
Prevalence of Perinatal Anxiety and Related Disorders in Low- and Middle-Income Countries
In many high-income countries, anxiety disorders are the most prevalent mental health disorders.1 They can arise more often during the perinatal period (from conception until 12 months post childbirth) than at other times in a woman’s life.2 Furthermore, perinatal anxiety and related disorders are associated with adverse outcomes for women and their babies.3 For the offspring, adverse outcomes include preterm birth, poor neurocognitive development, and longer-term outcomes, such as increased risk of cardiovascular disease and mental illness in adulthood.4,5 For women, perinatal anxiety disorders are associated with substance use disorders, recurrent mental illness, and suicide.6-8 Anxiety and related disorders (generalized anxiety disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, panic disorder, and adjustment disorder) are associated with a high burden of disease and economic cost.
- 1 November 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (11) , e2343711
Top Cited PapersOpen AccessPrevalence of Perinatal Anxiety and Related Disorders in Low- and Middle-Income Countries
In many high-income countries, anxiety disorders are the most prevalent mental health disorders.1 They can arise more often during the perinatal period (from conception until 12 months post childbirth) than at other times in a woman’s life.2 Furthermore, perinatal anxiety and related disorders are associated with adverse outcomes for women and their babies.3 For the offspring, adverse outcomes include preterm birth, poor neurocognitive development, and longer-term outcomes, such as increased risk of cardiovascular disease and mental illness in adulthood.4,5 For women, perinatal anxiety disorders are associated with substance use disorders, recurrent mental illness, and suicide.6-8 Anxiety and related disorders (generalized anxiety disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, panic disorder, and adjustment disorder) are associated with a high burden of disease and economic cost.
- Open Access
- 13 March 2023
- Published by BMJ in Open Heart
- Vol. 10 (1) , e002230
Patients’ understanding of long-term cardiovascular risks and associated health-seeking behaviours after pre-eclampsia
Objective The lifelong risks of cardiovascular disease following hypertensive disorders of pregnancy are well described. Awareness of these risks and associated health-seeking behaviours among affected individuals remains unclear. We aimed to assess participants’ knowledge of their cardiovascular disease risk and relevant health-seeking behaviours following a pregnancy affected by preeclampsia or gestational hypertension. Methods We undertook a single-site, cross-sectional cohort study. The target population included individuals who birthed at a large tertiary referral centre in Melbourne, Australia, between 2016 and 2020, and were diagnosed with gestational hypertension or pre-eclampsia. Participants completed a survey assessing pregnancy details, medical comorbidities, knowledge of future risks and health-seeking behaviours post-pregnancy. Results 1526 individuals met inclusion criteria and 438 (28.6%) completed the survey. Of these, 62.6% (n=237) were unaware of their increased risk of cardiovascular disease following a hypertensive disorder of pregnancy. Participants who reported awareness of their increased risk were more likely to have annual blood pressure monitoring (54.6% vs 38.1%, pConclusion Among our study cohort, risk awareness was associated with increased health-seeking behaviours. Participants who were aware of their increased risk of cardiovascular disease were more likely to have regular cardiovascular risk factor assessments. They were also more likely to be taking antihypertensive medication.
- 13 March 2023
- Published by BMJ in Open Heart
- Vol. 10 (1) , e002230
Open AccessPatients’ understanding of long-term cardiovascular risks and associated health-seeking behaviours after pre-eclampsia
Objective The lifelong risks of cardiovascular disease following hypertensive disorders of pregnancy are well described. Awareness of these risks and associated health-seeking behaviours among affected individuals remains unclear. We aimed to assess participants’ knowledge of their cardiovascular disease risk and relevant health-seeking behaviours following a pregnancy affected by preeclampsia or gestational hypertension. Methods We undertook a single-site, cross-sectional cohort study. The target population included individuals who birthed at a large tertiary referral centre in Melbourne, Australia, between 2016 and 2020, and were diagnosed with gestational hypertension or pre-eclampsia. Participants completed a survey assessing pregnancy details, medical comorbidities, knowledge of future risks and health-seeking behaviours post-pregnancy. Results 1526 individuals met inclusion criteria and 438 (28.6%) completed the survey. Of these, 62.6% (n=237) were unaware of their increased risk of cardiovascular disease following a hypertensive disorder of pregnancy. Participants who reported awareness of their increased risk were more likely to have annual blood pressure monitoring (54.6% vs 38.1%, pConclusion Among our study cohort, risk awareness was associated with increased health-seeking behaviours. Participants who were aware of their increased risk of cardiovascular disease were more likely to have regular cardiovascular risk factor assessments. They were also more likely to be taking antihypertensive medication.